Phase Forward and PharmaNet Development Group sign multi-year agreement

NewsGuard 100/100 Score

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with PharmaNet Development Group, Inc., a global drug development services company, that enables PharmaNet to offer Phase Forward’s InForm electronic data capture (EDC) solution to PharmaNet customers worldwide. PharmaNet provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries that includes clinical trial data management.

“We chose to team with Phase Forward on the basis of our successful collaboration on behalf of several pharmaceutical companies,” said Thomas Newman, M.D., President, PharmaNet Late Stage Development. “That experience indicated the complementary nature of Phase Forward’s established leadership in EDC technology solutions and our expertise in providing clinical trial services to a broad range of industries. We look forward to extending to other customers the success our work together has already achieved.”

“Customers are turning to PharmaNet for its proven expertise in providing the critical services infrastructure required to optimize the clinical trial process,” said Steve Powell, senior vice president, Phase Forward. “Our InForm EDC solution is a perfect addition to PharmaNet’s expertise and we look forward to building on and expanding our work together.”

Source:

Phase Forward

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance